Mangrove Partners’s Dyne Therapeutics DYN Stock Holding History

Mangrove Partners’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.06M	Hold	47,927	–	–	0.07%	124
2026 Q1	$869K	Buy	+47,927	New	+$826K	0.07%	121

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mangrove Partners's DYN Position: Q2 2026 in Review

Mangrove Partners held its Dyne Therapeutics (DYN) position steady in Q2 2026 at 47,927 shares worth $1.06M. The position accounts for 0.07% of the portfolio, ranked #124.

Mangrove Partners first reported a position in DYN in Q1 2026 and has held it in 2 quarters since. 245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

Mangrove Partners held 47,927 shares of Dyne Therapeutics worth $1.06M as of Q2 2026.
Mangrove Partners left its Dyne Therapeutics share count unchanged in Q2 2026.
Dyne Therapeutics made up 0.07% of Mangrove Partners's portfolio in Q2 2026, its #124 holding.
Mangrove Partners first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 2 quarters since.
245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.